Anti-Inflammatory Drug Incorporated Into Silicone Coating Reduces Foreign Body Reaction to Implants

Long-term use of implantable electronic medical devices – such as pacemakers and cochlear implants – is hampered by the body’s reaction to foreign bodies. Now, a new study in mice has shown that this reaction can be dramatically reduced by incorporating an anti-inflammatory drug into the silicone coating around the implant. The study by a team led by scientists at the University of Cambridge (Cambridge, UK) found that this prevented the foreign body reaction without affecting tissue regeneration.

Implantable electronic medical devices are already widely used for a number of applications, but they also offer the prospect of transforming the treatment of intractable conditions, such as the use of neural electrical stimulators for spinal injury patients. However, the human body recognizes, attacks and surrounds these implants with a dense, ‘protective’ capsule of scar tissue that prevents electrical stimulation reaching the nervous system.

This so-called ‘foreign body reaction’ is driven by an inflammatory response against the implant. First, immune cells known as macrophages attack and try to destroy the device. Then a more long-term response kicks in, again coordinated by the macrophages, which leads to the build-up of a collagen-rich capsule to separate it from the surrounding tissue. This response then persists until the implant is removed from the body. The mechanisms by which foreign body reaction occurs are poorly understood, meaning that there are no effective methods to prevent it without interfering with the tissue repair mechanisms, for example after nerve damage.

In the new study, scientists implanted an electrical device into mice to compensate for sciatic nerve damage and compared the response within the surrounding tissue to that in mice who did not receive an implant. As well as using normal mice, the researchers used mice whose genes controlling the inflammatory response had been ‘knocked out’, preventing a response. This allowed the team to see how the body’s inflammatory response generated the foreign body reaction, and which genes were involved. In turn, this showed that a particular molecule known as NLRP3 plays a key role.

The researchers then added a small molecule known as MCC950 to the device coating and tested its effect in the mice. MCC950 has previously been shown to inhibit the activity of NLRP3. They found that this prevented the foreign body reaction without affecting tissue regeneration. This contrasted with dexamethasone treatment, which prevents the foreign body reaction but also blocks nerve regeneration. NLRP3 inhibitors are being developed for a number of clinical applications including inflammatory disease, cancer, sepsis, Alzheimer’s disease and Parkinson’s disease. They are already being tested in clinical trials for certain conditions.

“There’s a lot of excitement around this new class of anti-inflammatory drugs. Once they’ve been through clinical trials and have been shown to be safe to use, we should be in a good position to integrate them into the next generation of implantable devices,” said joint senior author Professor Clare Bryant from the Department of Medicine at the University of Cambridge. “Combining these drugs with different materials and softer coatings for devices could transform the lives of individuals who need long-term implants to overcome serious disability or illness. In particular, this could make a huge difference to neuroprosthetics – prosthetics that connect to the nervous system – where the technology exists, but scarring has not yet made their widespread use viable.”

Related Links:
University of Cambridge 

Visit expo >

Gold Member

12-Channel ECG

CM1200B

Gold Member

POC Blood Gas Analyzer

Stat Profile Prime Plus

New

LED Surgical Light

Convelar 1670 LED+/1675 LED+/1677 LED+

New

Diagnosis Display System

C1216W